普洛藥業(000739.SZ):目前與百強連鎖基本都已經建立了合作
格隆匯4月19日丨普洛藥業(000739.SZ)於2024年4月18日進行投資者電話交流會,就“請問製劑研發思路如何?與和澤醫藥的合作情況?”,公司回覆稱,公司在佈局製劑研發品種時會考慮產品市場、產品定位和臨牀價值等因素。院內製劑是公司最重要的市場之一;同時,公司也在積極佈局終端市場品種,隨着三個終端市場的擴展,終端市場品種的放量也是必然的;目前,公司與百強連鎖基本都已經建立了合作。和澤醫藥是一家優秀的CRO研發公司,與和澤醫藥的戰略合作,一方面是基於對方優秀的研發團隊和資源,可以與公司研發資源相結合,使項目研發的效率更高;另一方面,對方的一些自有品種也能與公司形成製造方面的合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.